TrialEuropean journal of clinical pharmacology2015

Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.

Jeroen Diepstraten et al.PubMed ↗Publisher ↗

No numbers read from the abstract.